Total Payments
$54,919
2024 Payments
$149.28
Companies
16
Transactions
44
Medicare Patients
957
Medicare Billing
$410,546
Payment Breakdown by Category
Research$33,205 (60.5%)
Consulting$16,325 (29.7%)
Other$2,767 (5.0%)
Food & Beverage$1,338 (2.4%)
Travel$1,284 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $33,205 | 5 | 60.5% |
| Consulting Fee | $16,325 | 7 | 29.7% |
| Honoraria | $2,768 | 1 | 5.0% |
| Food and Beverage | $1,338 | 26 | 2.4% |
| Travel and Lodging | $1,284 | 5 | 2.3% |
Payments by Type
Research
$33,205
5 transactions
General
$21,714
39 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $32,783 | 4 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $11,248 | 9 | $0 (2022) |
| Aadi Bioscience, Inc. | $2,801 | 3 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $1,966 | 3 | $0 (2018) |
| Otsuka Pharmaceutical Co., Ltd. | $1,800 | 1 | $0 (2021) |
| Boehringer Ingelheim International GmbH | $1,470 | 1 | $0 (2023) |
| PFIZER INTERNATIONAL LLC | $625.00 | 1 | $0 (2018) |
| PTC Therapeutics, Inc. | $619.50 | 6 | $0 (2018) |
| GENZYME CORPORATION | $421.66 | 1 | $0 (2017) |
| Covidien LP | $390.00 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $149.28 | 1 | Deciphera Pharmaceuticals Inc. ($149.28) |
| 2023 | $1,604 | 2 | Boehringer Ingelheim International GmbH ($1,470) |
| 2022 | $14,068 | 13 | Boehringer Ingelheim Pharmaceuticals, Inc. ($11,248) |
| 2021 | $1,800 | 1 | Otsuka Pharmaceutical Co., Ltd. ($1,800) |
| 2020 | $540.00 | 3 | Covidien LP ($390.00) |
| 2019 | $8,284 | 1 | Eli Lilly and Company ($8,284) |
| 2018 | $28,012 | 19 | Eli Lilly and Company ($24,349) |
| 2017 | $461.40 | 4 | GENZYME CORPORATION ($421.66) |
All Payment Transactions
44 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/31/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $149.28 | General |
| Category: ONCOLOGY | ||||||
| 07/20/2023 | Abbott Laboratories | 2ND GEN CENTRIMAG PRIMARY CONSOLE (Device) | Food and Beverage | In-kind items and services | $134.20 | General |
| Category: Heart Failure | ||||||
| 07/04/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,470.00 | General |
| 11/16/2022 | Aadi Bioscience, Inc. | FYARRO (Drug) | Honoraria | Cash or cash equivalent | $2,767.50 | General |
| Category: IMMUNOSUPPRESSANT | ||||||
| 11/16/2022 | Aadi Bioscience, Inc. | FYARRO (Drug) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: IMMUNOSUPPRESSANT | ||||||
| 11/16/2022 | Aadi Bioscience, Inc. | FYARRO (Drug) | Food and Beverage | In-kind items and services | $4.69 | General |
| Category: IMMUNOSUPPRESSANT | ||||||
| 10/27/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,240.00 | General |
| 10/27/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $140.00 | General |
| 10/27/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 09/21/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $555.91 | General |
| 09/21/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $133.40 | General |
| 09/21/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $107.49 | General |
| 09/21/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $21.42 | General |
| 09/21/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $10.66 | General |
| 09/21/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $4.28 | General |
| 07/14/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: NEUROSCIENCE | ||||||
| 09/02/2021 | Otsuka Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 11/24/2020 | Covidien LP | — | Consulting Fee | Cash or cash equivalent | $193.00 | General |
| 11/20/2020 | Covidien LP | — | Consulting Fee | Cash or cash equivalent | $197.00 | General |
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $150.00 | Research |
| Study: A PHASE 1A/1B STUDY OF LY3405105 ADMINISTERED TO PATIENTS WITH ADVANCED SOLID TUMORS | ||||||
| 01/22/2019 | Eli Lilly and Company | — | — | Cash or cash equivalent | $8,284.00 | Research |
| Study: A PHASE 1B OPEN-LABEL - PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING GEMCITABINE AND DOCETAXEL WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA | ||||||
| 12/31/2018 | Eli Lilly and Company | — | — | Cash or cash equivalent | $21,764.00 | Research |
| Study: A PHASE 1B OPEN-LABEL - PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING GEMCITABINE AND DOCETAXEL WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA | ||||||
| 11/10/2018 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $91.78 | General |
| 11/10/2018 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $33.06 | General |
| 11/10/2018 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $23.81 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1B OPEN-LABEL - PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING GEMCITABINE AND DOCETAXEL WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA | Eli Lilly and Company | $30,048 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF DOXORUBICIN PLUS OLARATUMAB VERSUS DOXORUBICIN PLUS PLACEBO IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA | Eli Lilly and Company | $2,585 | 1 |
| A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Biological Activity of SAR405838 in Patients with Advanced Cancer | GENZYME CORPORATION | $421.66 | 1 |
| A PHASE 1A/1B STUDY OF LY3405105 ADMINISTERED TO PATIENTS WITH ADVANCED SOLID TUMORS | Eli Lilly and Company | $150.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 58 | 79 | $43,070 | $8,525 |
| 2022 | 4 | 261 | 653 | $282,850 | $93,147 |
| 2021 | 5 | 355 | 1,482 | $379,180 | $230,845 |
| 2020 | 4 | 283 | 575 | $189,920 | $78,029 |
Total Patients
957
Total Services
2,789
Medicare Billing
$410,546
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 22 | 36 | $16,710 | $2,897 | 17.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 26 | $13,780 | $2,885 | 20.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 17 | $12,580 | $2,744 | 21.8% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 95 | 270 | $43,200 | $43,123 | 99.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 78 | 220 | $116,600 | $23,695 | 20.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 61 | 136 | $100,640 | $21,433 | 21.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 27 | 27 | $22,410 | $4,896 | 21.8% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 190 | 1,115 | $178,400 | $181,104 | 101.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 69 | 182 | $87,060 | $20,852 | 24.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 59 | 126 | $80,590 | $20,721 | 25.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 23 | 23 | $19,090 | $4,878 | 25.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 36 | $14,040 | $3,289 | 23.4% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 151 | 273 | $43,680 | $43,213 | 98.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 60 | 168 | $72,140 | $16,051 | 22.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 54 | 116 | $59,160 | $15,249 | 25.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 18 | 18 | $14,940 | $3,516 | 23.5% |
About Dr. Gary Schwartz, MD
Dr. Gary Schwartz, MD is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164514337.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Schwartz, MD has received a total of $54,919 in payments from pharmaceutical and medical device companies, with $149.28 received in 2024. These payments were reported across 44 transactions from 16 companies. The most common payment nature is "" ($33,205).
As a Medicare-enrolled provider, Schwartz has provided services to 957 Medicare beneficiaries, totaling 2,789 services with total Medicare billing of $410,546. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location New York, NY
- Active Since 09/28/2006
- Last Updated 02/03/2017
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1164514337
Products in Payments
- FYARRO (Drug) $2,801
- Non-Covered $1,966
- SAR405838 (Drug) $421.66
- QINLOCK (Drug) $149.28
- 2ND GEN CENTRIMAG PRIMARY CONSOLE (Device) $134.20
- CentriMag (Device) $76.69
- PENTASA (Drug) $28.45
- QULIPTA (Drug) $19.23
- Rubraca (Drug) $12.90
- GATTEX (Drug) $11.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New York
Craig Thompson, Md, MD
Medical Oncology — Payments: $2.1M
Medical Oncology $2.1M
Andrew Seidman, Md, MD
Medical Oncology — Payments: $1.7M
Medical Oncology $1.7M
Dr. Joshua Richter, M.d, M.D
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Ghassan Abou-Alfa, Md, MD
Medical Oncology — Payments: $1.2M
Medical Oncology $1.2M
Edward Gelmann
Medical Oncology — Payments: $944,679
Medical Oncology $944,679
Miguel Perales, Md, MD
Medical Oncology — Payments: $759,555
Medical Oncology $759,555